沉默长链非编码PCAT-1对乳腺癌细胞阿霉素耐药性的影响
摘要
目的探究沉默长链非编码RNA (lncRNA) PCAT-1对乳腺癌细胞阿霉素(ADM)耐药性的影响。方法 qRTPCR实验检测PCAT-1的mRNA表达水平;通过小RNA干扰技术下调MCF7细胞中PCAT-1的表达,CCK-8和MTT实验检测MCF7、MCF7/ADM细胞增殖的活性; TUNEL实验检测MCF7/ADM细胞凋亡。结果 PCAT-1在乳腺癌组织和MCF7细胞中的mRNA表达水平明显高于癌旁组织和人乳腺上皮细胞MCF10A。PCAT-1在MCF7/ADM细胞的mRNA表达水平明显高于MCF7细胞。沉默PCAT-1可以促进ADM对MCF7、MCF7/ADM细胞增殖的抑制作用。沉默PCAT-1能够增强ADM诱导的MCF7/ADM细胞的凋亡。此外,沉默PCAT-1可以促进Bax的表达,抑制Bcl-2和PCNA的表达。结论沉默PCAT-1增强ADM对乳腺癌细胞的毒性作用。
引文
[1] Shi Y,Yang F,Sun Z,et al. Differential microRNA expression is associated with androgen receptor expression in breast cancer[J].Mol Med Report,2017,15(1):29-36.
[2] Donepudi MS,Kondapalli K,Amos SJ,et al. Breast cancer statistics and markers[J].J Cancer Res Ther,2014,10(3):506-511.
[3] Xu Y,Luo Y,Wang ZY,et al. MRTF-A can activate Nrf2 to increase the resistance to doxorubicin[J]. Oncotarget, 2017, 8(5):8436-8446.
[4] O'Driscoll L,Clynes M. Biomarkers and multiple drug resistance in breast cancer[J].Curr Cancer Drug Targets,2006,6(5):365-384.
[5]邵营波,张瑾.人类基因变异组计划及其在肿瘤方面研究进展[J].中国全科医学,2011,14(23):2706-2709.
[6] Li J,Meng H,Bai Y,et al. Regulation of lncRNA and its role in cancer metastasis[J]. Oncol Res,2016,23(5):205-217.
[7]陈宇宁,熊兴东.长链非编码RNA与表观遗传调控[J].生物化学与生物物理进展,2014,(8):723-730.
[8] Jiang M,Huang O,Xie Z,et al. A novel long non-coding RNAARA:adriamycin resistance-associated[J]. Biochem Pharmacol,2014,87(2):254-283.
[9] Sarrafzadeh S,Geranpayeh L,Ghafouri-Fard S. Expression analysis of long non-coding PCAT-1in breast cancer[J]. Int J Hematol Oncol Stem Cell Res,2017,11(3):185-191.
[10] Lage H,Aki-Sener E,Yalcin I. High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomeraseⅡ-targeting drugs[J]. Int J Cancer,2006,119(1):213-220.
[11] Prensner JR,Iyer MK,Balbin OA,et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1,an unannotated lincRNA implicated in disease progression[J]. Nat Biotechnol,2011,29(8):742-749.
[12] Xu W,Chang J,Du X,et al. Long non-coding RNA PCAT-1contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer[J]. Biomed Pharmacother,2017,95(11):1112-1118.
[13] Prensner JR,Chen W,Han S,et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through c Myc[J]. Neoplasia,2014,16(11):900-908.
[14] Zhang D,Cao J,Zhong Q,et al. Long noncoding RNA PCAT-1promotes invasion and metastasis via the miR-129-5p-HMGB1 signaling pathway in hepatocellular carcinoma[J]. Biomed Pharmacother,2017,95(11):1187-1193.
[15] Shi WH,Wu QQ,Li SQ,et al. Upregulation of the long noncoding RNA PCAT-1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma[J]. Tumour Biol,2015,36(4):2501-2507.
[16] Bi M,Yu H,Huang B,et al. Long non-coding RNA PCAT-1 over-expression promotes proliferation and metastasis in gastric cancer cells through regulating CDKN1A[J]. Gene,2017,626(8):337-343.
[17] Qiao L,Liu X,Tang Y,et al. Knockdown of long non-coding RNA prostate cancer-associated ncRNA transcript 1 inhibits multidrug resistance and c-Myc-dependent aggressiveness in colorectal cancer Caco-2 and HT-29 cells[J]. Mol Cell Biochem,2018,441(1-2):99-108.
[2] Donepudi MS,Kondapalli K,Amos SJ,et al. Breast cancer statistics and markers[J].J Cancer Res Ther,2014,10(3):506-511.
[3] Xu Y,Luo Y,Wang ZY,et al. MRTF-A can activate Nrf2 to increase the resistance to doxorubicin[J]. Oncotarget, 2017, 8(5):8436-8446.
[4] O'Driscoll L,Clynes M. Biomarkers and multiple drug resistance in breast cancer[J].Curr Cancer Drug Targets,2006,6(5):365-384.
[5]邵营波,张瑾.人类基因变异组计划及其在肿瘤方面研究进展[J].中国全科医学,2011,14(23):2706-2709.
[6] Li J,Meng H,Bai Y,et al. Regulation of lncRNA and its role in cancer metastasis[J]. Oncol Res,2016,23(5):205-217.
[7]陈宇宁,熊兴东.长链非编码RNA与表观遗传调控[J].生物化学与生物物理进展,2014,(8):723-730.
[8] Jiang M,Huang O,Xie Z,et al. A novel long non-coding RNAARA:adriamycin resistance-associated[J]. Biochem Pharmacol,2014,87(2):254-283.
[9] Sarrafzadeh S,Geranpayeh L,Ghafouri-Fard S. Expression analysis of long non-coding PCAT-1in breast cancer[J]. Int J Hematol Oncol Stem Cell Res,2017,11(3):185-191.
[10] Lage H,Aki-Sener E,Yalcin I. High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomeraseⅡ-targeting drugs[J]. Int J Cancer,2006,119(1):213-220.
[11] Prensner JR,Iyer MK,Balbin OA,et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1,an unannotated lincRNA implicated in disease progression[J]. Nat Biotechnol,2011,29(8):742-749.
[12] Xu W,Chang J,Du X,et al. Long non-coding RNA PCAT-1contributes to tumorigenesis by regulating FSCN1 via miR-145-5p in prostate cancer[J]. Biomed Pharmacother,2017,95(11):1112-1118.
[13] Prensner JR,Chen W,Han S,et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through c Myc[J]. Neoplasia,2014,16(11):900-908.
[14] Zhang D,Cao J,Zhong Q,et al. Long noncoding RNA PCAT-1promotes invasion and metastasis via the miR-129-5p-HMGB1 signaling pathway in hepatocellular carcinoma[J]. Biomed Pharmacother,2017,95(11):1187-1193.
[15] Shi WH,Wu QQ,Li SQ,et al. Upregulation of the long noncoding RNA PCAT-1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma[J]. Tumour Biol,2015,36(4):2501-2507.
[16] Bi M,Yu H,Huang B,et al. Long non-coding RNA PCAT-1 over-expression promotes proliferation and metastasis in gastric cancer cells through regulating CDKN1A[J]. Gene,2017,626(8):337-343.
[17] Qiao L,Liu X,Tang Y,et al. Knockdown of long non-coding RNA prostate cancer-associated ncRNA transcript 1 inhibits multidrug resistance and c-Myc-dependent aggressiveness in colorectal cancer Caco-2 and HT-29 cells[J]. Mol Cell Biochem,2018,441(1-2):99-108.